
    
      The duration of the study for each patient will include a screening period of up to 4 weeks,
      an induction period of 24 weeks (4 cycles with a duration of 42 ± 3 days), a continuous
      treatment period and a crossover period (when applicable). The cycle duration is 28 ± 3 days
      during the continuous treatment and crossover periods.
    
  